Please ensure Javascript is enabled for purposes of website accessibility

A Long-Term Play for Your Port

By Brian Orelli, PhD - Updated Apr 5, 2017 at 6:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Long-term prospects look better than the near term for Eli Lilly and its investors.

Eli Lilly (NYSE:LLY) is, like, so two days ago.

The company's guidance and future direction, as presented at an analyst meeting, looked much like Merck's (NYSE:MRK) presentation from two days earlier. Eli Lilly is even considering moving into selling copycat versions of biologic drugs -- just like Merck.

Earnings are expected to come in at $4.00 to $4.25 per share next year, which isn't much higher than the adjusted EPS of $3.97 to $4.02 the company is looking for this year. Note, though, that next year's earnings are being dragged down by $0.30 to $0.35 per share thanks to remaining costs from the acquisition of ImClone.

While it'll cost Eli Lilly's investors some earnings in the near term, the company really needed to make the major acquisition. Eli Lilly will lose quite a few drugs to patent expirations between now and 2014, and ImClone's pipeline should fill in the holes quite nicely.

Whether Eli Lilly will be able to make its guidance depends a lot on whether the FDA approves delayed blood thinner prasugrel, which will compete against Sanofi-Aventis' (NYSE:SNY) and Bristol-Myers Squibb's (NYSE:BMY) blockbuster Plavix.

In the longer term, Eli Lilly's looking pretty good. It has 59 drugs in the clinic and expects to launch one product per year between 2009 and 2012, including Amylin Pharmaceuticals' (NASDAQ:AMLN) once-weekly Byetta, which now appears to be back on track for a marketing application next year and a launch the year after.

Much like Merck, the near-term prospects for Eli Lilly aren't anything to get excited about. But the pharmaceutical industry looks like a good long-term bet -- especially at these depressed prices. In the meantime, investors can enjoy their 5% yield while they wait.

Eli Lilly is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$308.08 (2.63%) $7.89
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$91.02 (2.35%) $2.09
Sanofi Stock Quote
$44.37 (2.19%) $0.95
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$75.57 (1.49%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.